385 reports of this reaction
2.0% of all RAVULIZUMAB reports
#9 most reported adverse reaction
MALAISE is the #9 most commonly reported adverse reaction for RAVULIZUMAB, manufactured by Alexion Pharmaceuticals Inc.. There are 385 FDA adverse event reports linking RAVULIZUMAB to MALAISE. This represents approximately 2.0% of all 19,021 adverse event reports for this drug.
Patients taking RAVULIZUMAB who experience malaise should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALAISE is a less commonly reported adverse event for RAVULIZUMAB, but still significant enough to appear in the safety profile.
In addition to malaise, the following adverse reactions have been reported for RAVULIZUMAB:
The following drugs have also been linked to malaise in FDA adverse event reports:
MALAISE has been reported as an adverse event in 385 FDA reports for RAVULIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALAISE accounts for approximately 2.0% of all adverse event reports for RAVULIZUMAB, making it a notable side effect.
If you experience malaise while taking RAVULIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.